The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

Amgen has invested in Carmot Therapeutics having previously licensed a cancer drug candidate from the company that is currently in phase 2 clinical trials.

The dental services startup boosted its total funding to $73m in a round led by GV, with the cash to support the opening of new clinics.

Johnson & Johnson-backed surgical technology developer Cardiac Dimensions has now raised more than $172m altogether.

McKesson Ventures, Novartis Venture Fund and Merck Global Health Innovation Fund took part in a round for biomarker developer Koneska.

University of Milan spinout Wise is a developer of low-invasive neuromodulation implants for treating pain and neurological disorders.

Sophia Genetics has added Hitachi to its list of shareholders following a $110m series F round that also included returning backer Swisscom.

The insurance provider has committed $100m to the Life Science Impact Program, which is managed by Grove Street Advisors and will focus on healthcare businesses.

Lyell Immunopharma was joined by new corporate backers Lilly Asia Ventures Biosciences and Alexandria Venture Investments to bring Sonoma’s series A round to $70m.

The insurer has put $54m into a corporate venturing arm called SwissHealth Ventures to target digital health startups.